Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist (rhIL1RA) for Sepsis Varies by Initial IL1RA Plasma Concentration

OBJECTIVE: Plasma interleukin-1 beta (IL1β) may influence sepsis mortality, yet recombinant human interleukin-1 receptor antagonist (rhIL1RA) did not reduce mortality in randomized trials. We tested for heterogeneity in the treatment effect of rhIL1RA by baseline plasma IL1β or IL1RA concentration....

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Crit Care Med
Main Authors: Meyer, Nuala J., Reilly, John P., Anderson, Brian J., Palakshappa, Jessica A., Jones, Tiffanie K., Dunn, Thomas G., Shashaty, Michael G.S., Feng, Rui, Christie, Jason D., Opal, Steven M.
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5734955/
https://ncbi.nlm.nih.gov/pubmed/28991823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCM.0000000000002749
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares